摘要
程序性细胞死亡蛋白-1以及程序性细胞死亡配体-1(PD-1/PD-L1)抑制剂是临床常见的免疫检查点抑制剂(ICIs),广泛应用于多种癌症的免疫治疗。然而,PD-1/PD-L1抑制剂在临床应用过程中可能发生全身各系统的免疫不良反应事件(irAEs),对患者治疗预后造成不利影响。文章对PD-1/PD-L1抑制剂常见的irAEs以及irAEs的影响因素进行综述,从患者基本特征、药物使用方式、癌症类型、流感疫苗和微生物菌群等角度分析各种因素对irAEs的影响,为临床更好地选择治疗方案和管理PD-1/PD-L1抑制剂引发的irAEs提供思路。
Programmed cell death protein-1 and programmed cell death ligand-1(PD-1/PD-L1)inhibitors are immune checkpoint inhibitors(ICIS),which are widely used in the immunotherapy of a variety of cancers.However,during the clinical application of PD-1/PD-L1 inhibitors,immune-related adverse events(irAEs)may occur in various systems,which will adversely affect the treatment prognosis of patients.This paper reviews the common irAEs of PD-1/PD-L1 inhibitors and the influencing factors of iraes,and the effects of various factors on irAEs will be summarized from the perspectives of patients,drug use,cancer types,influenza vaccines and microflora in order to provide ideas for better treatment selection and management of irAEs induced by PD-1/PD-L1 inhibitors.
作者
宗明溪
朱颖(综述)
詹娟(审校)
ZONG Ming-xi;ZHU Ying;ZHAN Juan(School of Medicine,Xiamen University,Xiamen 361102,Fujian,China;Department of Oncology,Zhongshan Hospital Affiliated to Xiamen University,Xiamen 361004,Fujian,China)
出处
《医学研究生学报》
CAS
北大核心
2022年第11期1219-1225,共7页
Journal of Medical Postgraduates
基金
厦门市医疗卫生科技计划项目(3502Z20194021)。
